Last reviewed · How we verify
NCT06735794: STEP-MC
Impact of Spaced iTBS on Plasticity in the Motor Cortex
NA trial testing Compressed iTBS in Healthy Control Subjects in 29 participants. Completed in 1 February 2026.
1 February 2026
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 29 |
| Start date | 13 November 2024 |
| Primary completion | 1 February 2026 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Compressed iTBS
- Spaced iTBS
- Sham iTBS
Conditions studied
- Healthy Control Subjects — all drugs for Healthy Control Subjects →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
Adults 18 to 50, any sex, with Healthy Control Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to explore the effects of non-invasive brain stimulation protocols using intermittent theta-burst stimulation (iTBS) on brain plasticity in healthy, right-handed individuals aged 18 to 50 years. Brain plasticity is the brain's ability to change through growth or reorganization. iTBS is a form of transcranial magnetic stimulation (TMS), where magnetic pulses are applied to the scalp using a coil. These pulses pass through the scalp, and can alter brain activity in the area underneath the coil. Based on previous research conducted in animals and humans, researchers believe that iTBS can strengthen the connections between cells in the brain, leading to improved brain plasticity. This trial will compare the effects of the compressed iTBS (iTBS-c) protocol, which is commonly used to treat depression, and the spaced iTBS (iTBS-s) protocol. Researchers want to find out which protocol is better able to produce changes in brain plasticity. Sham iTBS (iTBS-sh) will be used as a control to make the results of the study more reliable. Participants will complete 5 study visits within the span of 3 months, including: * Screening assessments to determine eligibility (Visit 1); * Calibration iTBS session (Visit 2) to assess tolerability of brain stimulation; * Three experimental iTBS sessions (iTBS-s, iTBS-c, and iTBS-sh) in a randomized order (Visits 3-5), each separated by at least 72 hours. During each session, the study team will stimulate the motor cortex and record the muscle activity of your hand to measure changes in brain plasticity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06735794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06735794 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06735794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing